politics

Japanese Startup Trials Catheter Injection of iPS Heart Muscle Cells

13 Haziran 2026Japan Times

A Tokyo-based startup is testing a new method for delivering iPS heart muscle cells via catheter injection. This innovative approach aims to provide a minimally invasive treatment option that eliminates the need for traditional surgery.
The company's research could pave the way for advancements in cardiac care and regenerative medicine.
Induced pluripotent stem (iPS) cells have garnered attention for their potential to regenerate damaged tissues, particularly in the heart. The ability to deliver these cells through a catheter could revolutionize treatment for heart disease, which remains a leading cause of mortality worldwide.
The development of catheter-based delivery systems for iPS cells represents a significant shift in how cardiac treatments may be approached in the future. If successful, this method could not only reduce recovery times but also lower the risks associated with surgical interventions.

NewsAI özeti

This article is for informational purposes only and does not constitute medical advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.